knowledge -WSS

knowledge

author：knowledge 2025-09-28 15:57:04 - browse：84

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Skip the lead apron during X

Wikipedia

WSS

The pink breast cancer awareness ribbon needs a redesign

Medtronic CEO on promising devices for diabetes, hypertension

The wait for US passports is creating travel purgatory and snarling summer plans

Medtronic CEO on promising devices for diabetes, hypertension

Lupron, used to halt puberty in children, may cause lasting health problems

Prescription digital therapeutics are key to pharma’s future

focus

knowledge

explore

Malaria cases in Florida and Texas: Here’s what you need to know

Use doctors trained outside the U.S. to ease the physician shortage

Heart attack and stroke risk calculators need revising

Cassava reveals details — and problems — with Alzheimer's study

Supreme Court strikes down use of affirmative action

Maker of FluMist seeks to allow at

Malaria cases in Florida and Texas: Here’s what you need to know

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Trump demands the U.S. pay no more for drugs than other countries … again

A letter from the executive editor: The 2023 STATUS List

explore

Why Sanofi got shellacked over its spinoff

Maker of FluMist seeks to allow at

Hubble vs. James Webb telescope images: See the difference

Emergency medicine has repudiated 'excited delirium.' Now what?

Dexcom's push to bring CGM to type 2 diabetes patients

Vertex cell therapy lets patients with type 1 diabetes stop insulin

hotspot

Wikipedia

focus

focus